J&J, Novartis Fined $22.4M Over Pay-For-Delay Deal

Law360, New York (December 10, 2013, 1:06 PM ET) -- Drugmakers Johnson & Johnson and Novartis AG on Tuesday were hit with a total of €16.3 million ($22.4 million) in fines by European regulators for entering into an anti-competitive agreement to delay the introduction of a generic painkiller in the Netherlands.

The European Commission said in 2005 that the respective Dutch subsidiaries of Novartis and J&J entered into a deal to prevent the entry of a generic version of J&J's fentanyl, after the protection on its brand-name fentanyl depot patch expired in the Netherlands, just as...
To view the full article, take a free trial now.
Try Law360 for free for seven days
Already a subscriber? Click here to login

Already have access?

  1. Forgot your password?
  2. Sign In

Get instant access to the one-stop news source for business lawyers

Required